The investment opportunity in immunocontraceptive vaccines
A clinical-stage biopharmaceutical firm has gotten investor attention lately following news of its xpansion into aquaculture with an innovative vaccines company that is out to revolutionize reproductive control in farmed fish and wildlife management, presenting a lucrative investment opportunity.
BioVaxys Technology Corp. (CSE:BIOV) has expanded its license agreement with SpayVac for Wildlife Inc. for access to BioVaxys’ patented liposome-based delivery platform for no-booster fertility-control vaccines in the commercial aquaculture and farm-raised fish markets. This move could significantly broaden SpayVac’s market reach and revenue potential, presenting a compelling investment opportunity for BioVaxys stakeholders.
Expansion of license agreement
The expanded license agreement encompassing the commercial aquaculture and farm-raised fish markets. supplements SpayVac’s current vaccine line-up waiting regulatory approval for immunocontraception for overabundant feral / wild / invasive animals, and development for select production and companion animals. This expansion opens up new commercial avenues, particularly in the global market for farm-raised Atlantic salmon and rainbow trout.
Market opportunity in aquaculture
The global market for farm-raised Atlantic salmon and rainbow trout represents a substantial commercial opportunity for SpayVac. According to Seafish, a U.K.-based public body supporting the aquaculture industry, the annual harvest of these two species totals approximately 3.28 million metric tons, equating to an estimated 800 million individual fish. This presents a significant addressable market for SpayVac’s contraceptive vaccines, which are being developed as an alternative to triploidy—a form of genetic manipulation commonly used in aquaculture to induce sterility.
Advantages of SpayVac’s immunocontraceptive approach
SpayVac’s immunocontraceptive approach offers producers a scalable and cost-effective solution for reproductive control in farmed fish, requiring only a single dose. This method is simple and economical, leveraging a patented liposome-based delivery platform developed by BioVaxys and licensed to SpayVac. The liposomes encapsulate the antigen and improve the immune system’s response to vaccination, targeting different points in the reproductive system.
Proven efficacy and ongoing trials
Multiple clinical trials have demonstrated SpayVac-pZP’s single-dose, long-lasting (four to 10 years) immunocontraceptive efficacy in various animals, including seals, feral horses, and several species of deer. Trials with farmed trout, macaques, and African and Asian elephants are ongoing. Initial proof-of-concept trials in aquaculture are well underway, with the program advancing to the second phase of development, focusing on optimizing the timing of injection within the fish’s life cycle.
Regulatory approval and market adoption
SpayVac has initiated the submission process to secure regulatory approval for its first product targeting feral horses and free-ranging deer populations. The U.S. Bureau of Land Management is a potential lead customer, supporting an ongoing study in feral horses to determine differences in immunocontraceptive efficacy based on injection site. Positive results from this study are expected to drive adoption of SpayVac in future management of feral horse and burro populations in the western U.S.
Global impact and market potential
The challenge of managing feral horse populations is not limited to the United States. In Australia, the feral horse population is expanding across various regions, with an estimated 400,000 feral horses growing by an average of 18 per cent a year. SpayVac’s single-dose, long-duration immunocontraceptive product is anticipated to be a game-changer, offering a more efficient and cost-effective solution compared to current pZP-based products that require multiple boosters.
Leadership insights
“Based on the superior profile of SpayVac vaccines and the U.S. market potential with feral horses and deer, we are anticipating a healthy revenue stream from royalties on sales of SpayVac,” Kenneth Kovan, the company’s president and COO explained in a media release. “With huge global markets for horses and deer, such as Australia, and the expansion into commercial aquaculture including the farm-raised fish market, SpayVac is positioned to become a significant player in the animal health field.”
Investor’s corner
BioVaxys’ expansion of its license agreement with SpayVac for Wildlife puts the company on a solid path to capitalize on significant market opportunities in aquaculture and wildlife management.
With proven efficacy, ongoing trials, and a clear path to regulatory approval, SpayVac’s innovative immunocontraceptive approach offers a disruptive solution with substantial revenue potential. Investors are encouraged to conduct further due diligence into BioVaxys Technology Corp. to explore this promising investment opportunity.
Join the discussion: Find out what everybody’s saying about this stock on the Biovaxys Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
This is sponsored content issued on behalf of BioVaxys Technology Corp., please see full disclaimer here.
(Top image via BioVaxys Technology Corp.)